HAMP and nutritional disorder: Hepcidin therapy thus has the potential to accomplish the equivalent of “chemical therapeutic phlebotomy” and might reduce the need for cytoreductive therapy in low-risk PV patients with symptomatic iron deficiency and/or high phlebotomy requirements.